Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $93.95 which represents a slight increase of $0.55 or 0.59% from the prior close of $93.4. The stock opened at $93 and touched ...

Victoryshares Free Cash Flow ETF's index reconstitution and portfolio changes signal a strategy shift. See why I recommend ...

Assembly Biosciences, Inc. (ASMB), a biotechnology company, Thursday announced encouraging interim data from Phase 1b study of ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...

Shares of Gilead Sciences Inc. GILD inched 0.59% higher to $93.95 Tuesday, on what proved to be an all-around positive ...

The first round of the U.S.’ Medicare negotiations accounted for a lot of digital ink and headlines in 2024. Next year is sure to bring more of the same as Medicare is to announce up to 15 Part D ...

First, the good news about pandemics – and in 2024, there was big “good news.” Science Magazine named lenacapavir (Gilead Sciences Inc.) as the Breakthrough of the Year. In two separate trials, ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

From Pfizer to AstraZeneca and the Omnicom-IPG Merger, the industry has seen a number of executive moves during this year.